The authors shed light on the mechanistic view of MSC therapeutic role based on preclinical and clinical studies on acute lung injury and ARDS; therefore, offering a unique correlation and applicability in COVID-19 patients. They further highlight the challenges and opportunities in the use of MSC-based therapy.
[Stem Cell Research & Therapy]
6630899 VCT7TDK4 items 1 apa default asc 1
Arch Biopartners, Inc. announced it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.
[Arch Biopartners, Inc.]
6445218 nan items 1 apa default asc 1
Researchers investigated the mechanism underneath MSC-reversed lung injury and fibrosis. They determined that coculture with MSC led to the inactivation of NF-κB signaling and therefore suppressed the hedgehog pathway in LPS-treated MLE-12 cells.
[Cell Death & Disease]
6630899 R9NC53U5 items 1 apa default asc 1
Xiao, K., He, W., Guan, W., Hou, F., Yan, P., Xu, J., Zhou, T., Liu, Y., & Xie, L. (2020). Mesenchymal stem cells reverse EMT process through blocking the activation of NF-κB and Hedgehog pathways in LPS-induced acute lung injury. Cell Death & Disease, 11(10), 1–17. https://doi.org/10.1038/s41419-020-03034-3 Cite
Scientists discuss the possibility of using various approved drugs, or drugs currently in clinical development, to treat COVID-19. They suggest to enhance STAT1 activity and/or inhibit STAT3 functions for COVID-19 treatment.
[Cell Death & Differentiation]
Investigators showed that CD8+ T cells played an important role in MSC-mediated acute lung injury remission, and both infiltration quantity and proinflammatory function were inhibited by MSCs, indicating a potential mechanism for therapeutic intervention.
[Cell Death & Disease]
6630899 PXMMWLRJ items 1 apa default asc 1
Zhu, J., Feng, B., Xu, Y., Chen, W., Sheng, X., Feng, X., Shi, X., Liu, J., Pan, Q., Yu, J., Li, L., & Cao, H. (2020). Mesenchymal stem cells alleviate LPS-induced acute lung injury by inhibiting the proinflammatory function of Ly6C + CD8 + T cells. Cell Death & Disease, 11(10), 1–11. https://doi.org/10.1038/s41419-020-03036-1 Cite
Single-cell transcriptome analysis identified brain-derived neurotrophic factor as a STAT3 target gene with newly accessible chromatin in a unique population of regenerating AT2 cells.
[Nature Cell Biology]
6445218 RF6PBFQN items 1 apa default asc 1
Paris, A. J., Hayer, K. E., Oved, J. H., Avgousti, D. C., Toulmin, S. A., Zepp, J. A., Zacharias, W. J., Katzen, J. B., Basil, M. C., Kremp, M. M., Slamowitz, A. R., Jayachandran, S., Sivakumar, A., Dai, N., Wang, P., Frank, D. B., Eisenlohr, L. C., Cantu, E., Beers, M. F., … Worthen, G. S. (2020). STAT3–BDNF–TrkB signalling promotes alveolar epithelial regeneration after lung injury. Nature Cell Biology, 1–14. https://doi.org/10.1038/s41556-020-0569-x Cite
Alveolar epithelial type II cells (AE2) of young mice adapted to injury by increasing intracellular surfactant volume and proliferation rate. In old mice, however, this adaptive response was compromised and AE2 of old mice showed signs of cell senescence, increased inflammatory signaling and impaired surfactant metabolism in acute lung injury.
[American Journal of Physiology-Lung Cellular and Molecular Physiology]
6606345 GLR5Q7AP items 1 apa default asc 1
The authors investigated whether and how ruscogenin (RUS) exerted therapeutic effects on PM-induced acute lung injury. RUS was orally administered to mice prior to or after intratracheal instillation of particulate matter suspension.
[Acta Pharmacologica Sinica]
6445212 I2LYLJAL items 1 apa default asc 1
Wang, Y., Wu, Y., Zhang, J., Tang, J., Fan, R., Li, F., Yu, B., Kou, J., & Zhang, Y. (2020). Ruscogenin attenuates particulate matter-induced acute lung injury in mice via protecting pulmonary endothelial barrier and inhibiting TLR4 signaling pathway. Acta Pharmacologica Sinica, 1–9. https://doi.org/10.1038/s41401-020-00502-6 Cite
Acute lung injury-induced HMGB1 leaked and was captured by arterial macrophages thereby altering their mitochondrial metabolism through RIPK3.
6445212 57DHEL8E items 1 apa default asc 1
Boytard, L., Hadi, T., Silvestro, M., Qu, H., Kumpfbeck, A., Sleiman, R., Fils, K. H., Alebrahim, D., Boccalatte, F., Kugler, M., Corsica, A., Gelb, B. E., Jacobowitz, G., Miller, G., Bellini, C., Oakes, J., Silvestre, J.-S., Zangi, L., & Ramkhelawon, B. (2020). Lung-derived HMGB1 is detrimental for vascular remodeling of metabolically imbalanced arterial macrophages. Nature Communications, 11(1), 4311. https://doi.org/10.1038/s41467-020-18088-2 Cite
Vasomune Therapeutics announced it has received a Peer-Reviewed Medical Research Program grant award effective August 1, 2020 for US $2.8 million from the US Department of Defense for the development AV-001 for the treatment of COVID-19-associated acute lung injury and acute respiratory distress syndrome.
Investigators found lipopolysaccharide significantly increased inflammatory factors, administration of exosomes released by human umbilical cord MSCs successfully improved lung morphometry.
[Cell Death & Disease]
6445212 ZZGN9HSC items 1 apa default asc 1
Wei, X., Yi, X., Lv, H., Sui, X., Lu, P., Li, L., An, Y., Yang, Y., Yi, H., & Chen, G. (2020). MicroRNA-377-3p released by mesenchymal stem cell exosomes ameliorates lipopolysaccharide-induced acute lung injury by targeting RPTOR to induce autophagy. Cell Death & Disease, 11(8), 1–14. https://doi.org/10.1038/s41419-020-02857-4 Cite